03.14.12
Prismic Pharmaceuticals, Scottsdale, AZ, has acquired the assets of Scarista Limited, along with Scarista's exclusive license from Amarin Neuroscience Limited (a wholly owned subsidiary of Amarin Corporation) to develop, market and out-license products based on a portfolio of issued U.S. and foreign composition and use patents covering highly purified forms of omega 3 fatty acids alone or in combination with other molecules for the treatment of disorders of the central nervous system (CNS).
“Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area,” said Peter Moriarty, chairman and co-founder of Prismic. "There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously."
“Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area,” said Peter Moriarty, chairman and co-founder of Prismic. "There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously."